Armata Operating Margin from 2010 to 2025

ARMP Stock  USD 1.95  0.04  2.01%   
Armata Pharmaceuticals Operating Profit Margin yearly trend continues to be relatively stable with very little volatility. Operating Profit Margin is likely to drop to -10.9.
Check Armata Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Armata Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 3.2 M or Selling General Administrative of 10 M, as well as many indicators such as Price To Sales Ratio of 28.2, Dividend Yield of 0.0175 or Days Sales Outstanding of 256. Armata financial statements analysis is a perfect complement when working with Armata Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Armata Pharmaceuticals Correlation against competitors.
To learn how to invest in Armata Stock, please use our How to Invest in Armata Pharmaceuticals guide.

Latest Armata Pharmaceuticals' Operating Margin Growth Pattern

Below is the plot of the Operating Profit Margin of Armata Pharmaceuticals over the last few years. It is Armata Pharmaceuticals' Operating Profit Margin historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Armata Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (3.28) %10 Years Trend
Pretty Stable
   Operating Profit Margin   
       Timeline  

Armata Operating Margin Regression Statistics

Arithmetic Mean(30.40)
Geometric Mean18.67
Coefficient Of Variation(119.39)
Mean Deviation23.68
Median(20.75)
Standard Deviation36.30
Sample Variance1,317
Range135
R-Value0.17
Mean Square Error1,369
R-Squared0.03
Significance0.52
Slope1.32
Total Sum of Squares19,762

Armata Operating Margin History

2025 -10.9
2024 -10.38
2023 -9.03
2022 -6.71
2021 -5.32
2018 -26.23
2017 -140.49

About Armata Pharmaceuticals Financial Statements

Armata Pharmaceuticals shareholders use historical fundamental indicators, such as Operating Margin, to determine how well the company is positioned to perform in the future. Although Armata Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Armata Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Armata Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It has a partnership agreement with Merck Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. Armata Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 69 people.

Additional Tools for Armata Stock Analysis

When running Armata Pharmaceuticals' price analysis, check to measure Armata Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Armata Pharmaceuticals is operating at the current time. Most of Armata Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Armata Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Armata Pharmaceuticals' price. Additionally, you may evaluate how the addition of Armata Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.